home / stock / crbu / crbu news

CRBU News and Press, Caribou Biosciences Inc. From 07/06/23

Stock Information
Company Name: Caribou Biosciences Inc.
Stock Symbol: CRBU
Market: NASDAQ
Website: cariboubio.com
Menu
CRBU CRBU Quote CRBU Short CRBU News CRBU Articles CRBU Message Board
Get CRBU Alerts

News, Short Squeeze, Breakout and More Instantly...
CRBU - Why Shares of Caribou Biosciences Are Skyrocketing Today

2023-07-06 11:54:56 ET Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the company. The healthcare stock is up more than 3% ...
CRBU - Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s Scientific Advisory Board -- BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE...

CRBU - PRTS, CRBU and NDLS are among after hour movers

2023-06-09 17:15:14 ET Gainers: PepGen  ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital  ( APLD ) +3% . Losers: Couchbase ( BASE ...

CRBU - Caribou Biosciences: Like Watching Paint Dry

2023-05-31 17:31:40 ET Summary We circle back to allogenic (off-the-shelf) cell therapy concern Caribou Biosciences for the first time since last Spring. Caribou is advancing three early-stage candidates within its pipeline, and the stock trades for the net cash on the company's b...
CRBU - Caribou Bioscience GAAP EPS of -$0.46 beats by $0.03, revenue of $3.50M beats by $0.35M

2023-05-09 17:28:13 ET Caribou Bioscience press release ( NASDAQ: CRBU ): Q1 GAAP EPS of -$0.46 beats by $0.03 . Revenue of $3.50M (+31.6% Y/Y) beats by $0.35M . For further details see: Caribou Bioscience GAAP EPS of -$0.46 beats by $0.03, revenue of $3....

CRBU - Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 -- -- CB-012 IND application for r/r AML planned for H2 2023 ...

CRBU - Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the ap...
CRBU - CRSP, OCUL and EYPT are among after hour movers

2023-04-20 17:51:34 ET Gainers: ContextLogic ( WISH ) +28% . EyePoint Pharmaceuticals ( EYPT ) +7% . Caribou Biosciences ( CRBU ) +5% . Ocular Therapeutix ( OCUL ) +3% . Coherus BioSciences ( CHRS ) +3% . Losers: CRISPR T...

CRBU - Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 -- BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Carib...

CRBU - Caribou stock pops on FDA fast track tag for blood cancer therapy CB-011

2023-04-04 08:58:11 ET The U.S. Food and Drug Administration (FDA) granted fast track designation to Caribou Biosciences' ( NASDAQ: CRBU ) allogeneic CAR-T cell therapy CB-011 to treat relapsed or refractory multiple myeloma (r/r MM). CB-011 is being evaluated in a phase 1 tri...
Previous 10 Next 10